Scientists closer to slowing progression of Alzheimer's

September 7, 2018, Wits University
Credit: CC0 Public Domain

A breakthrough by Wits scientists could see patients with Alzheimer's use a nasal spray to slow down the progression of the disease, the main cause of dementia.

Alzheimer's, which starts out with loss of memory and problems with thought processing, becomes an especially debilitating disease as it progresses—it attacks parts of the brain that control walking, coordination and even swallowing. Mood swings, aggression, repetition, and volatile behaviour are typical as the disease takes hold, making life for patients, their families and caregivers difficult.

"If we can slow down the progression of the disease, we can dramatically improve the quality of life for patients, as well as extend their lifespan. In advanced stages, Alzheimer's can affect the functioning of the whole body and eventually lead to death," says Stefan Weiss, lead researcher and Professor in the School of Molecular and Cell Biology in the Faculty of Science at Wits University.

Until now, there has been no cure for treating Alzheimer's, which viciously attacks brain cells when proteins group together and deposit amyloid-beta plaque. But Professor Weiss and his team of researchers from Wits, including Dr. Eloise Ferreira, Dr. Monique Bignoux, Tyrone Otgaar, Nicolas Tagliatti, Katarina Jovanovic and (the late) Dr. Boitelo Letsolo have discovered an antibody that effectively targets the protein aggregation itself.

"We conducted mouse studies which showed that the anti-LRP/LR specific antibody rescues cells from A-beta induced cytotoxicity and A-beta secretion. What this means is that the antibody significantly reduces , a hallmark for Alzheimer's disease. This suggested that the antibody might delay the progression of Alzheimer's disease in mice:- it is the amyloid plaques which ravage brain cells.

We administered the antibody nasally, twice a week for eight weeks. By effectively reducing amyloid plaque formation, we saw improvements in memory and cognitive functions in the mice."

Their study, funded by the South African Medical Research Council, was initiated in 2015. It has taken three years to perform the study, analyse the results, and publish the paper. Now Weiss and his team are planning Phase 1 of the clinical trials with 30 to 50 volunteers suffering from Alzheimer's.

The team expects to see similar results as with the mice, i.e., a significant improvement of memory and cognitive functions in the Alzheimer's disease patients. If the outcomes are as expected, the team hopes to get regulatory approval on the nasal spray containing the anti-LRP/LR specific antibody. The could then be available to Alzheimer's patients in the near future.

"We ideally need a pharmaceutical partner to be involved in this next study, to carry out further clinical trials and to subsequently commercialise the drug," says Anne Gabathuse, Innovation Support Manager at Wits Commercial Enterprise (Pty) Ltd. (Wits Enterprise), which is assisting Weiss in further development and commercial negotiations.

Wits Enterprise's Innovation Support is mandated by Wits to manage and commercialise intellectual property that emanates from research at the university. Through the development of products, processes and services with social and economic impact, Innovation Support has worked with Weiss and his team to file for patent protection for the antibody.

Weiss is very hopeful about the clinical trial on Alzheimer's patients and about the new hope that the antibody treatment may bring: "Alzheimer's patients have had no way of tackling their disease, aside from medicines to reduce pain and discomfort. With the anti-LRP/LR specific antibody, there is the potential to actually target the protein clumping and stop the formation of amyloid plaque.

"Although we have not conducted any study into the potential of the antibody as a prophylactic drug for preventing Alzheimer's, it is certainly a possibility. For now, our focus is to have the antibody administered as a therapeutic for Alzheimer's disease patients."

Gabathuse says: "This discovery is indeed a giant leap forward in the treatment of Alzheimer's disease and we are very excited about the recent results obtained from the mouse studies. We are looking forward to the next stage of the project, which is to investigate whether the compound will be as effective in humans as it has been in the mice."

"The number of people living with symptoms of Alzheimer's disease globally is estimated at 35 million with the lives of millions of others—such as their families, colleagues and caregivers—indirectly affected. It is clear to see what the far-reaching, positive impact of the antibody could be for society."

Explore further: Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

Related Stories

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Can aspirin treat Alzheimer's?

July 2, 2018
A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological researchers at Rush University Medical Center, who published ...

Antibody removes Alzheimer's plaques, in mice

March 26, 2018
Years before people start showing characteristic symptoms of Alzheimer's disease, sticky plaques begin forming in their brains, damaging nearby cells. For decades, doctors have sought ways to clear out these plaques as a ...

Can nanotechnology help treat Alzheimer's?

June 19, 2018
Alzheimer's disease (AD) is the most common form of dementia. It takes a devastating toll on patients and family members, who are usually the caregivers. Current drugs only treat symptoms of AD, not its causes.

Study shows antibody therapy clears Alzheimer's plaques in mice

December 5, 2012
Antibodies against amyloid beta (Aβ) protein deposits that are thought to play a role in Alzheimer's disease have shown some success in preventing the buildup of deposits in animals, but they have not been effective at removing ...

Possible solution for side effect of Alzheimer's immunotherapy treatment

November 5, 2015
It is estimated that 46.8 million people worldwide are living with dementia, with Alzheimer's disease the most common form.

Recommended for you

Air pollution may be linked to heightened dementia risk

September 18, 2018
Air pollution may be linked to a heightened risk of developing dementia, finds a London-based observational study, published in the online journal BMJ Open. The associations found couldn't be explained by factors known to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

Study prevents cognitive decline in older blacks with memory loss

September 10, 2018
With nearly twice the rate of dementia as whites, blacks are at a higher risk for developing diseases like Alzheimer's, but there has been little research on how to reduce this racial health disparity. A new study in black ...

Excessive daytime sleepiness linked with brain protein involved in Alzheimer's disease

September 6, 2018
Analysis of data captured during a long-term study of aging adults shows that those who report being very sleepy during the day were nearly three times more likely than those who didn't to have brain deposits of beta amyloid, ...

Study shows how exercise generates new neurons, improves cognition in Alzheimer's mouse

September 6, 2018
A study by a Massachusetts General Hospital (MGH) research team finds that neurogenesis -inducing the production of new neurons—in the brain structure in which memories are encoded can improve cognitive function in a mouse ...

Novel strategy shows promise for earlier detection of Alzheimer's disease

September 4, 2018
Finding an effective way to identify people with mild cognitive impairment who are most likely to go on to develop Alzheimer's disease has eluded researchers for years. But now, a team of researchers led by David Loewenstein, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.